biologic

Coagadex

Coagulation Factor X (Human)

Loss of exclusivityOctober 2027projected — 12-year biologic exclusivity estimate
CompanyBio Products Laboratory Limited

Drug detail

Brand nameCoagadex
Active ingredientCoagulation Factor X (Human)
Strength250IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Coagadex patent cliff — loss of exclusivity October 2027 | CliffBio